Template:HSV-1 antiviral treatment: Difference between revisions
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
===Anti-viral Treatment=== | ===Anti-viral Treatment=== | ||
====Normal Host==== | |||
* | *Options: | ||
**[[Acyclovir]] 40-80mg/kg PO divided in 3-4 doses for 5-7 days | **[[Acyclovir]] | ||
***Can also be used as a cream or oral suspension (swish and swallow)<ref name="Mohan">Mohan RPS, Verma S, Singh U, Agarwal N. Acute primary herpetic gingivostomatitis. BMJ Case Reports. 2013;2013:bcr2013200074. doi:10.1136/bcr-2013-200074.</ref> | ***400 mg PO 5x/day (q4hrs while awake) x 5 days, OR | ||
**[[Valacyclovir]] ( | ***40-80mg/kg PO divided in 3-4 doses for 5-7 days, OR | ||
**[[Famciclovir]] | ****Can also be used as a cream or oral suspension (swish and swallow)<ref name="Mohan">Mohan RPS, Verma S, Singh U, Agarwal N. Acute primary herpetic gingivostomatitis. BMJ Case Reports. 2013;2013:bcr2013200074. doi:10.1136/bcr-2013-200074.</ref> | ||
**[[Famciclovir]] 500mg PO BID x 7 days, OR | |||
**[[Valacyclovir]] 2gm PO q12 x 1 day | |||
====Immunocompromised==== | |||
*Options: | |||
**[[Acyclovir]] | |||
***5 mg/kg IV (over 1 hours) q8h x 7 days, OR | |||
***400mg PO 5x/day x 14-21 days | |||
**[[Famciclovir]] 500mg PO BID x 7 days, OR | |||
**[[Valacyclovir]] 500mg PO BID x 5-10 days | |||
Latest revision as of 20:59, 26 April 2016
Anti-viral Treatment
Normal Host
- Options:
- Acyclovir
- 400 mg PO 5x/day (q4hrs while awake) x 5 days, OR
- 40-80mg/kg PO divided in 3-4 doses for 5-7 days, OR
- Can also be used as a cream or oral suspension (swish and swallow)[1]
- Famciclovir 500mg PO BID x 7 days, OR
- Valacyclovir 2gm PO q12 x 1 day
- Acyclovir
Immunocompromised
- Options:
- Acyclovir
- 5 mg/kg IV (over 1 hours) q8h x 7 days, OR
- 400mg PO 5x/day x 14-21 days
- Famciclovir 500mg PO BID x 7 days, OR
- Valacyclovir 500mg PO BID x 5-10 days
- Acyclovir
- ↑ Mohan RPS, Verma S, Singh U, Agarwal N. Acute primary herpetic gingivostomatitis. BMJ Case Reports. 2013;2013:bcr2013200074. doi:10.1136/bcr-2013-200074.